ATE206123T1 - Phenylxanthin-derivate - Google Patents

Phenylxanthin-derivate

Info

Publication number
ATE206123T1
ATE206123T1 AT95927805T AT95927805T ATE206123T1 AT E206123 T1 ATE206123 T1 AT E206123T1 AT 95927805 T AT95927805 T AT 95927805T AT 95927805 T AT95927805 T AT 95927805T AT E206123 T1 ATE206123 T1 AT E206123T1
Authority
AT
Austria
Prior art keywords
pct
sec
date
pub
date jan
Prior art date
Application number
AT95927805T
Other languages
English (en)
Inventor
Susan Mary Daluge
Helen Lyng White
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE206123T1 publication Critical patent/ATE206123T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
AT95927805T 1994-08-01 1995-07-31 Phenylxanthin-derivate ATE206123T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415529A GB9415529D0 (en) 1994-08-01 1994-08-01 Phenyl xanthine derivatives
PCT/GB1995/001808 WO1996004280A1 (en) 1994-08-01 1995-07-31 Phenyl xanthine derivatives

Publications (1)

Publication Number Publication Date
ATE206123T1 true ATE206123T1 (de) 2001-10-15

Family

ID=10759232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927805T ATE206123T1 (de) 1994-08-01 1995-07-31 Phenylxanthin-derivate

Country Status (9)

Country Link
US (1) US5776940A (de)
EP (1) EP0775141B1 (de)
JP (1) JPH10503767A (de)
AT (1) ATE206123T1 (de)
AU (1) AU3181395A (de)
DE (1) DE69522947T2 (de)
ES (1) ES2162934T3 (de)
GB (1) GB9415529D0 (de)
WO (1) WO1996004280A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ATE242293T1 (de) 1998-06-02 2003-06-15 Crompton Vinyl Additives Gmbh Cyanacetylharnstoffe zum stabilisieren von halogenhaltigen polymeren
EP0967245A1 (de) 1998-06-26 1999-12-29 Witco Vinyl Additives GmbH 1,3-disubstituierte 6-Aminouracile zum Stabilisieren von halogenhaltigen Polymeren
EP0967209B1 (de) 1998-06-26 2003-01-08 Crompton Vinyl Additives GmbH Neue NH2-modifizierte 6-Aminouracile als Stabilisatoren für halogenhaltige Polymere
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
WO2002007721A2 (en) * 2000-07-20 2002-01-31 Lauras As Use of cox-2 inhibitors for preventing immunodeficiency
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
US7304070B2 (en) * 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
ATE520694T1 (de) * 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
EP1496911B1 (de) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
SI1789053T1 (sl) * 2004-09-01 2012-09-28 Gilead Sciences Inc Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US20080187487A1 (en) * 2006-05-03 2008-08-07 Gustavo Larsen Methods for producing multilayered particles, fibers and sprays and methods for administering the same
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
US5300298A (en) * 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
TW252044B (de) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤

Also Published As

Publication number Publication date
ES2162934T3 (es) 2002-01-16
DE69522947T2 (de) 2002-04-11
DE69522947D1 (en) 2001-10-31
GB9415529D0 (en) 1994-09-21
WO1996004280A1 (en) 1996-02-15
EP0775141B1 (de) 2001-09-26
JPH10503767A (ja) 1998-04-07
US5776940A (en) 1998-07-07
AU3181395A (en) 1996-03-04
EP0775141A1 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
ATE206123T1 (de) Phenylxanthin-derivate
MX9203053A (es) Derivados de aza nor bornano.
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
BR9509708B1 (pt) compostos e composições endoparasiticidas.
FI932229A0 (fi) Azabicykliska bryggderivat
NO963439L (no) Sammensetninger inneholdende mikronisert vebivolol
DE69515183D1 (de) Hypolipidämische benzothiazepine
ATE177749T1 (de) Spiroketalderivate, diese enthaltende zusammensetzungen und ihre verwendung als arzneimittel
AP1408A (en) Phenyl yanthine derivatives.
FI945975A0 (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
DE69516503D1 (de) Piperidinderivate mit paf antagonistischer wirkung
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties